1
|
Liaw YF and Chu CM: Hepatitis B virus
infection. Lancet. 373:582–592. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chen L, Zhao H, Yang X, Gao JY and Cheng
J: HBsAg-negative hepatitis B virus infection and hepatocellular
carcinoma. Discov Med. 18:189–193. 2014.PubMed/NCBI
|
3
|
Tujios SR and Lee WM: Update in the
management of chronic hepatitis B. Curr Opin Gastroenterol.
29:250–256. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Gale MJ and Katze MG: Molecular mechanisms
of interferon resistance mediated by viral-directed inhibition of
PKR, the interferon-induced protein kinase. Pharmacol Ther.
78:29–46. 1998. View Article : Google Scholar : PubMed/NCBI
|
5
|
Garcia MA, Gil J, Ventoso I, Guerra S,
Domingo E, Rivas C and Esteban M: Impact of protein kinase PKR in
cell biology: From antiviral to antiproliferative action. Microbiol
Mol Biol Rev. 70:1032–1060. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Niederau C, Heintges T, Lange S, Goldmann
G, Niederau CM, Mohr L and Häussinger D: Long-term follow-up of
HBeAg-positive patients treated with interferon alfa for chronic
hepatitis B. N Engl J Med. 334:1422–1427. 1996. View Article : Google Scholar : PubMed/NCBI
|
7
|
Zoulim F and Locarnini S: Management of
treatment failure in chronic hepatitis B. J Hepatol. 56:(Suppl 1).
S112–S122. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Song ZL, Cui YJ, Zheng WP, Teng DH and
Zheng H: Diagnostic and therapeutic progress of multi-drug
resistance with anti-HBV nucleos(t)ide analogues. World J
Gastroenterol. 18:7149–7157. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Ikeda M, Abe K, Yamada M, Dansako H, Naka
K and Kato N: Different anti-HCV profiles of statins and their
potential for combination therapy with interferon. Hepatology.
44:117–125. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Potena L, Frascaroli G, Grigioni F,
Lazzarotto T, Magnani G, Tomasi L, Coccolo F, Gabrielli L, Magelli
C, Landini MP and Branzi A: Hydroxymethyl-glutaryl coenzyme a
reductase inhibition limits cytomegalovirus infection in human
endothelial cells. Circulation. 109:532–536. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bader T and Korba B: Simvastatin
potentiates the anti-hepatitis B virus activity of FDA-approved
nucleoside analogue inhibitors in vitro. Antiviral Res. 86:241–245.
2010. View Article : Google Scholar : PubMed/NCBI
|
12
|
Bruemmer D, Yin F, Liu J, Kiyono T, Fleck
E, Van Herle A, Graf K and Law RE: Atorvastatin inhibits expression
of minichromosome maintenance proteins in vascular smooth muscle
cells. Eur J Pharmacol. 462:15–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
13
|
Maiorano D, Lutzmann M and Méchali M: MCM
proteins and DNA replication. Curr Opin Cell Biol. 18:130–136.
2006. View Article : Google Scholar : PubMed/NCBI
|
14
|
Namdar M and Kearsey SE: Analysis of
Mcm2-7 chromatin binding during anaphase and in the transition to
quiescence in fission yeast. Exp Cell Res. 312:3360–3369. 2006.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Shechter D, Ying CY and Gautier J: DNA
unwinding is an Mcm complex-dependent and ATP hydrolysis-dependent
process. J Biol Chem. 279:45586–45593. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Gonzalez MA, Tachibana KE, Laskey RA and
Coleman N: Control of DNA replication and its potential clinical
exploitation. Nat Rev Cancer. 5:135–141. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Nishitani H and Lygerou Z: Control of DNA
replication licensing in a cell cycle. Genes Cells. 7:523–534.
2002. View Article : Google Scholar : PubMed/NCBI
|
18
|
Masuda T, Mimura S and Takisawa H: CDK-
and Cdc45-dependent priming of the MCM complex on chromatin during
S-phase in Xenopus egg extracts: Possible activation of MCM
helicase by association with Cdc45. Genes Cells. 8:145–161. 2003.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Aladjem MI: Replication in context:
Dynamic regulation of DNA replication patterns in metazoans. Nat
Rev Genet. 8:588–600. 2007. View
Article : Google Scholar : PubMed/NCBI
|
20
|
Simon NE and Schwacha A: The Mcm2-7
replicative helicase: A promising chemotherapeutic target. Biomed
Res Int. 2014:5497192014. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lee JK and Hurwitz J: Isolation and
characterization of various complexes of the minichromosome
maintenance proteins of Schizosaccharomyces pombe. J Biol Chem.
275:18871–18878. 2000. View Article : Google Scholar : PubMed/NCBI
|
22
|
Lee JK and Hurwitz J: Processive DNA
helicase activity of the minichromosome maintenance proteins 4, 6,
and 7 complex requires forked DNA structures. Proc Natl Acad Sci
USA. 98:54–59. 2001. View Article : Google Scholar : PubMed/NCBI
|
23
|
Kawaguchi A and Nagata K: De novo
replication of the influenza virus RNA genome is regulated by DNA
replicative helicase, MCM. EMBO J. 26:4566–4575. 2007. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhou YM, Zhang XF, Cao L, Li B, Sui CJ, Li
YM and Yin ZF: MCM7 expression predicts post-operative prognosis
for hepatocellular carcinoma. Liver Int. 32:1505–1509. 2012.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Sonenberg N and Dever TE: Eukaryotic
translation initiation factors and regulators. Curr Opin Struct
Biol. 13:56–63. 2003. View Article : Google Scholar : PubMed/NCBI
|
27
|
Shi Y, Vattem KM, Sood R, An J, Liang J,
Stramm L and Wek RC: Identification and characterization of
pancreatic eukaryotic initiation factor 2 alpha-subunit kinase,
PEK, involved in translational control. Mol Cell Biol.
18:7499–7509. 1998. View Article : Google Scholar : PubMed/NCBI
|
28
|
Schmitt E, Naveau M and Mechulam Y:
Eukaryotic and archaeal translation initiation factor 2: A
heterotrimeric tRNA carrier. FEBS Lett. 584:405–412. 2010.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Kim JH, Park SM, Park JH, Keum SJ and Jang
SK: eIF2A mediates translation of hepatitis C viral mRNA under
stress conditions. EMBO J. 30:2454–2464. 2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Isaacs A and Lindenmann J: Virus
interference. I. The interferon. Proc R Soc Lond B Biol Sci.
147:258–267. 1957. View Article : Google Scholar : PubMed/NCBI
|
31
|
Zhang S, Sun Y, Chen H, Dai Y, Zhan Y, Yu
S, Qiu X, Tan L, Song C and Ding C: Activation of the PKR/eIF2α
signaling cascade inhibits replication of Newcastle disease virus.
Virol J. 11:622014. View Article : Google Scholar : PubMed/NCBI
|
32
|
Trinh MA, Ma T, Kaphzan H, Bhattacharya A,
Antion MD, Cavener DR, Hoeffer CA and Klann E: The eIF2α kinase
PERK limits the expression of hippocampal metabotropic glutamate
receptor-dependent long-term depression. Learn Mem. 21:298–304.
2014. View Article : Google Scholar : PubMed/NCBI
|
33
|
Harding HP, Zhang Y, Bertolotti A, Zeng H
and Ron D: Perk is essential for translational regulation and cell
survival during the unfolded protein response. Mol Cell. 5:897–904.
2000. View Article : Google Scholar : PubMed/NCBI
|
34
|
Rutkowski DT and Kaufman RJ: A trip to the
ER: Coping with stress. Trends Cell Biol. 14:20–28. 2004.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Ron D and Walter P: Signal integration in
the endoplasmic reticulum unfolded protein response. Nat Rev Mol
Cell Biol. 8:519–529. 2007. View
Article : Google Scholar : PubMed/NCBI
|
36
|
Avivar-Valderas A, Bobrovnikova-Marjon E,
Diehl J Alan, Bardeesy N, Debnath J and Aguirre-Ghiso JA:
Regulation of autophagy during ECM detachment is linked to a
selective inhibition of mTORC1 by PERK. Oncogene. 32:4932–4940.
2013. View Article : Google Scholar : PubMed/NCBI
|
37
|
Shaw RJ: LKB1 and AMP-activated protein
kinase control of mTOR signalling and growth. Acta Physiol (Oxf).
196:65–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
38
|
Shackelford DB and Shaw RJ: The LKB1-AMPK
pathway: Metabolism and growth control in tumour suppression. Nat
Rev Cancer. 9:563–575. 2009. View
Article : Google Scholar : PubMed/NCBI
|